Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +62

Zacks Research Weighs in on Humana's Q4 Earnings (NYSE:HUM)

AI-generated analysis

πŸ“ˆ Zacks Research raised Q4 2026 EPS estimates to $6.07 from $6.08 and maintains a 'Strong-Buy' rating on Humana.

πŸ’° The company reported Q1 FY2026 EPS of $10.31, beating analyst consensus of $9.97 by $0.34.

πŸ“Š Revenue reached $39.65 billion, surpassing estimates of $39.37 billion with 23.5% year-over-year growth.

🎯 Goldman Sachs raised its price target to $195 but retains a 'sell' rating on the stock.

πŸ“ˆ JPMorgan Chase increased its price objective from $214 to $316 while assigning a 'neutral' rating.

🏦 Vanguard Group increased its stake by 0.7% in Q4, now holding 14.26 million shares valued at $3.65 billion.

πŸ“‰ Capital International Investors raised its position by 113.9%, adding over 3 million shares to its portfolio.

🏒 Massachusetts Financial Services Co. boosted its holdings by 28.9% in the fourth quarter.

πŸ“… Humana has set full-year 2026 earnings guidance at $9.00 per share.

πŸ“‰ The stock trades with a P/E ratio of 42.84 and a market capitalization of $48.09 billion.

Bullish Signals
  • Zacks Research upgraded its Q4 2026 EPS forecast to $6.07, reflecting improved analyst expectations for the company's profitability.
  • Humana beat quarterly earnings estimates by $0.34 per share and revenue estimates by $280 million, demonstrating strong operational execution.
  • Revenue grew 23.5% year-over-year to $39.65 billion, indicating robust demand for the company's Medicare Advantage and commercial plans.
  • Major institutional investors including Vanguard, Capital International, and Massachusetts Financial Services increased their stakes significantly in Q4.
  • JPMorgan Chase raised its price target by over $100 to $316, signaling confidence in the stock's long-term value despite a neutral rating.
  • The company achieved a return on equity of 10.45% and maintained healthy liquidity ratios with both quick and current ratios at 1.77.
Risk Factors
  • Goldman Sachs maintains a 'sell' rating on Humana despite raising its price target, suggesting concerns about valuation or competitive positioning.
  • The stock carries a high P/E ratio of 42.84, which may indicate that the market is pricing in significant future growth expectations.
  • Analyst ratings are split, with 15 analysts holding a 'Hold' rating and two issuing a 'Sell', creating mixed sentiment around the current price.
Full Analysis
Zacks Research has raised its Q4 2026 earnings per share (EPS) estimate for Humana Inc. to $6.07, up from a previous forecast of $6.08, maintaining a 'Strong-Buy' rating. The consensus full-year EPS estimate stands at $9.53, with Zacks also projecting Q4 2027 earnings at $1.91. This analyst upgrade follows a period of significant movement in broker price targets and ratings for the health insurance provider. Humana recently reported strong financial results for the quarter ended April 29th, posting EPS of $10.31 which beat the consensus estimate of $9.97 by $0.34. The company generated revenue of $39.65 billion, exceeding analyst expectations of $39.37 billion, with year-over-year revenue growth of 23.5%. Key financial metrics included a net margin of 0.82%, a return on equity of 10.45%, and the company has set its FY 2026 guidance at $9.00 EPS. Market sentiment remains mixed among major brokerages, with Goldman Sachs raising its price target to $195 while maintaining a 'sell' rating, contrasted by upgrades from JPMorgan Chase, Sanford Bernstein, and Wolfe Research which have issued higher price objectives or strong-buy ratings. The stock currently trades at an average analyst target of $325.87 based on MarketBeat data, with the firm holding a market capitalization of $48.09 billion. Institutional ownership has seen notable increases in the fourth quarter, with Vanguard Group growing its stake by 0.7% to own over 14 million shares valued at approximately $3.65 billion. Other significant holders like Capital International Investors and Massachusetts Financial Services Co. also increased their positions substantially, indicating continued institutional interest despite the varied analyst ratings.